These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 5493764)

  • 1. [Reactogenic and sensitizing properties of cholera vaccine].
    Klots VI
    Zh Mikrobiol Epidemiol Immunobiol; 1970 Mar; 47(3):68-71. PubMed ID: 5493764
    [No Abstract]   [Full Text] [Related]  

  • 2. [Anti-cholera vaccination and its secondary effects. Cutaneous lesions observed in mass vaccination].
    Márton K; Márton-Ecsi
    Int J Dermatol; 1972; 11(2):112-5. PubMed ID: 5024029
    [No Abstract]   [Full Text] [Related]  

  • 3. [Evaluation of tolerability of an anticholera vaccine].
    Del Vecchio V; D'Arca SU; Melino C
    Nuovi Ann Ig Microbiol; 1972; 23(1):1-8. PubMed ID: 4660365
    [No Abstract]   [Full Text] [Related]  

  • 4. [Intracutaneous vaccination technic with less side effects against typhoid and cholera].
    Peltola H; Ruutu P; Palomäki H; Kaukinen K; Aho K
    Duodecim; 1977; 93(7):431-8. PubMed ID: 322994
    [No Abstract]   [Full Text] [Related]  

  • 5. [Neurological complications of cholera vaccination in childhood (epidemiological studies, clinical aspects, follow-up)].
    Giordano GG; Militerni R; Madia S
    Pediatria (Napoli); 1978 Jun; 86(2):221-31. PubMed ID: 704226
    [No Abstract]   [Full Text] [Related]  

  • 6. A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali.
    Perry RT; Plowe CV; Koumaré B; Bougoudogo F; Kotloff KL; Losonsky GA; Wasserman SS; Levine MM
    Bull World Health Organ; 1998; 76(1):63-71. PubMed ID: 9615498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study on the immunogenicity and safety of recombinant B-subunit/whole cell cholera vaccine infused with antacids in healthy population at ages of 2-6 years].
    Huang T; Li RC; Liu DP
    Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Sep; 51(9):827-831. PubMed ID: 28881549
    [No Abstract]   [Full Text] [Related]  

  • 8. Adverse events after oral vaccination against cholera with CVD103-HgR.
    Wiedermann G; Kollaritsch H; Jeschko E; Kundi M; Herzog C; Wegmüller B
    Wien Klin Wochenschr; 1998 May; 110(10):376-8. PubMed ID: 9654693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Episode resembling immune complex disease after cholera vaccination.
    Mall T; Gyr K
    Trans R Soc Trop Med Hyg; 1984; 78(1):106-7. PubMed ID: 6231747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mass vaccination with a two-dose oral cholera vaccine in a long-standing refugee camp, Thailand.
    Phares CR; Date K; Travers P; Déglise C; Wongjindanon N; Ortega L; Bhuket PR
    Vaccine; 2016 Jan; 34(1):128-33. PubMed ID: 26549363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholera and typhoid vaccine. The current state of play.
    Cohen J
    Aust Fam Physician; 1997 Aug; 26(8):943-6. PubMed ID: 9267060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mass psychogenic illness following oral cholera immunization in Ca Mau City, Vietnam.
    Khiem HB; Huan le D; Phuong NT; Dang DH; Hoang DH; Phuong le T; Sac PK; Chien TM; Tai LA; Dan NT; Deen JL; Seidlein Lv; Clemens J; Trach DD
    Vaccine; 2003 Nov; 21(31):4527-31. PubMed ID: 14575763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled field trial of the effectiveness of cholera and cholera El Tor vaccines in Calcutta.
    Das Gupta A; Sinha R; Shrivastava DL; De SP; Taneja BL; Rao MS; Abou-Gareeb AH
    Bull World Health Organ; 1967; 37(3):371-85. PubMed ID: 5301381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The characteristics of the reactogenicity and immunological activity of a new cholera bivalent chemical vaccine based on the results of controlled trials].
    Sumarokov AA; Ivanov NR; Dzhaparidze MN; Rystsova EA; Reznikov IuB; Matusevich LIa; Nikitina GP; Eliseev IuIu; Adamova GV; Plotnikova MN
    Zh Mikrobiol Epidemiol Immunobiol; 1991 Jul; (7):55-8. PubMed ID: 1719716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A controlled field trial of plain and aluminium hydroxide-adsorbed cholera vaccines in Surabaya, Indonesia, during 1973--75.
    Saroso JS; Bahrawi W; Witjaksono H; Budiarso RL; Brotowasisto ; Bencić Z; Dewitt WE; Gomez CZ
    Bull World Health Organ; 1978; 56(4):619-27. PubMed ID: 365388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Intradermal inoculation in anti-cholera vaccination].
    Gallut J
    Med Trop (Mars); 1971; 31(1):124-6. PubMed ID: 5576842
    [No Abstract]   [Full Text] [Related]  

  • 17. Benefit versus risk factors in cholera and typhoid immunization.
    Joó I
    Dev Biol Stand; 1979; 43():47-52. PubMed ID: 520686
    [No Abstract]   [Full Text] [Related]  

  • 18. Randomized placebo controlled human volunteer trial of a live oral cholera vaccine VA1.3 for safety and immune response.
    Mahalanabis D; Ramamurthy T; Nair GB; Ghosh A; Shaikh S; Sen B; Thungapathra M; Ghosh RK; Pazhani GP; Nandy RK; Jana S; Bhattacharya SK
    Vaccine; 2009 Jul; 27(35):4850-6. PubMed ID: 19523608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, immunogenicity, and lot stability of the whole cell/recombinant B subunit (WC/rCTB) cholera vaccine in Peruvian adults and children.
    Taylor DN; Cárdenas V; Perez J; Puga R; Svennerholm AM
    Am J Trop Med Hyg; 1999 Dec; 61(6):869-73. PubMed ID: 10674661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A case of Guillain-Barré syndrome following cholera vaccination (author's transl)].
    Schrader H
    J Neurol; 1975; 209(1):69-74. PubMed ID: 50424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.